| Bladder Non-Urothelial Carcinoma studied in …STUDIED_INderived16 of 16show fewer |
|---|
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 16 trials mapped (7 active) | — | — | Bladder Small Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06041503Phase 2 · recruiting Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161532Phase 2 · recruiting Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756569Phase 2 · recruiting Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology · condition mapped ONTOLOGY_EXACT · 16 trials mapped (7 active) | — | — | Bladder Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped CURATED_BROADER · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03582475Phase 1 · active not recruiting Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate · condition mapped ONTOLOGY_EXACT · 16 trials mapped (7 active) | — | — | Bladder Small Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03912818Phase 2 · terminated Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · condition mapped CURATED_BROADER · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01954173NA · terminated Adjuvant Radiation for High Risk Bladder Cancer · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03430895Phase 2 · completed Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04815629unknown Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01611662Phase 2 · terminated Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00072137Phase 1 · terminated Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy · condition mapped CURATED_BROADER · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00407485Phase 2 · completed VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112905Phase 2 · terminated Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005831Phase 2 · completed Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer · condition mapped ALIAS · 16 trials mapped (7 active) | — | — | Bladder Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |